New immunotherapy duo takes on tough esophageal cancer
NCT ID NCT04785820
First seen Apr 18, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This phase 2 trial tested two new experimental drugs, lomvastomig and tobemstomig, against the standard immunotherapy nivolumab in 190 people with advanced esophageal cancer that had stopped responding to chemotherapy. The drugs are designed to boost the immune system's ability to fight cancer. The study was completed, but enrollment in the lomvastomig group was stopped early for strategic reasons, not safety concerns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHP - Hopital Saint Antoine
Paris, 75571, France
-
Ac?badem Altunizade Hastanesi
Istanbul, Turkey (Türkiye)
-
Asan Medical Center
Seoul, 05505, South Korea
-
Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department
Erzurum, 25240, Turkey (Türkiye)
-
Azienda Sanitaria Universitaria Integrata di Udine - PO Universitario Santa Maria della
Udine, Friuli Venezia Giulia, 33100, Italy
-
Bashkirian Republican Clinical Oncology Dispensary
Ufa, Bashkortostan Republic, 450054, Russia
-
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital
Adana, 01230, Turkey (Türkiye)
-
Centre Leon Berard
Lyon, 69373, France
-
Centro Oncologico Riojano Integral (CORI)
La Rioja, F5300COE, Argentina
-
Centrum Onkologii w Bydgoszczy
Bydgoszcz, 85-796, Poland
-
Changhua Christian Hospital
Chang-hua, 500, Taiwan
-
Chonnam National University Hwasun Hospital
Jeollanam-do, 58128, South Korea
-
Communal Non profit Enterprise Regional Center of Oncology
Kharkiv, Kharkiv Governorate, 61070, Ukraine
-
Complejo Hospitalario de Navarra
Pamplona, Navarre, 31008, Spain
-
Curie Oncology
Singapore, 329563, Singapore
-
Dicle Uni Medical Faculty
Diyarbakır, 10000, Turkey (Türkiye)
-
Fakultni nemocnice Olomouc
Olomouc, 779 00, Czechia
-
First Moscow State Medical University n.a. I.M. Sechenov
Moscow, Moscow Oblast, 119991, Russia
-
Group of companies "Medci"
Moskva, Moscow Oblast, 105229, Russia
-
Hopital Claude Huriez
Lille, 59037, France
-
Hopital Timone Adultes
Marseille, 13385, France
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Clínic i Provincial
Barcelona, 08036, Spain
-
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
-
ICO Rene Gauducheau
Saint-Herblain, 44805, France
-
IRCCS Istituto Oncologico Veneto (IOV)
Padova, Veneto, 35128, Italy
-
Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department
Malatya, 44280, Turkey (Türkiye)
-
Inst. Alexander Fleming
Buenos Aires, C1426ANZ, Argentina
-
Institut régional du Cancer Montpellier
Montpellier, 34298, France
-
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, 01246-000, Brazil
-
International Cancer Institute (ICI)
Eldoret, 30100, Kenya
-
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
Meldola, Emilia-Romagna, 47014, Italy
-
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
Szolnok, 5004, Hungary
-
Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II
Krakow, 31-202, Poland
-
MEDSI Clinical Hospital on Pyatnitsky Highway
Moscow, Moscow Oblast, 143422, Russia
-
Masaryk?v onkologický ústav
Brno, 656 53, Czechia
-
NIO im Marii Sklodowskiej-Curie
Warsaw, 02-034, Poland
-
National Cancer Centre
Singapore, 168583, Singapore
-
National Taiwan University Hospital
Zhongzheng Dist., 10048, Taiwan
-
Nottingham City Hospital
Nottingham, NG5 1PB, United Kingdom
-
Odense Universitetshospital, Onkologisk Afdeling R
Odense C, 5000, Denmark
-
Ramathibodi Hospital
Bangkok, 10400, Thailand
-
Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary
Sumy, 40005, Ukraine
-
Rigshospitalet
København Ø, 2100, Denmark
-
Seoul National University Bundang Hospital
Seongnam-si, 13605, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Siriraj Hospital
Bangkok, 10700, Thailand
-
Songklanagarind Hospital
Songkhla, 90110, Thailand
-
Szpital Morski im. PCK
Gdynia, 81-519, Poland
-
Taipei Veterans General Hospital
Taipei, 112201, Taiwan
-
The Aga Khan University-Kenya.
Nairobi, 00100, Kenya
-
Van Yuzuncu Yil University Hospital
Van, Turkey (Türkiye)
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lomvastomig and tobemstomig (bispecific antibodies) compared to nivolumab (Opdivo)
What this could lead to
If successful, these new antibodies could offer a more effective immunotherapy option for people with advanced esophageal cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a phase 2 trial, so results are still early. One of the drugs (lomvastomig) was stopped for strategic reasons, not safety, but its future is uncertain. The study is also relatively small (190 people).
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.